ES-004

N/A

Report date: 2024/04/02 14:24:55

Base Information

Drug NameES-004
Drug Alias NameES-004ES 004-N4ES 004-B4
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionSignal-regulatory protein alpha inhibitorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants
TargetsSignal-regulatory protein alpha
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesElpiscience (Shanghai) Biopharma Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesElpiscience (Suzhou) Biopharma Ltd
Inactive CompaniesElpiscience (Shanghai) Biopharma Ltd
Active IndicationsSolid tumours
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A